Eli Lilly and Company — 2020 Form 10-K Summary
Business context and reporting period
This filing reports the fiscal year ended December 31, 2020. Although the request references 2020 Q4, the supplied 10-K presents full-year results; it does not provide a clear standalone fourth-quarter financial summary. Lilly operates as a single segment focused on human pharmaceutical products. Diabetes products remained its largest product group.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $24.54 billion | $22.32 billion | +10% |
| Gross margin | $19.06 billion; 77.7% of revenue | $17.60 billion; 78.8% | +8% dollars; down 1.1 percentage points |
| Operating expenses (R&D and marketing, selling, and administrative) | $12.21 billion | $11.81 billion | +3% |
| Income before income taxes | $7.23 billion | $5.27 billion | +37% |
| Net income from continuing operations | $6.19 billion | $4.64 billion | +34% |
| Net income, including discontinued operations | $6.19 billion | $8.32 billion | -26% |
| Diluted EPS from continuing operations | $6.79 | $4.96 | +37% |
| Total net cash from operating activities | $6.50 billion | $4.84 billion | +34% |
Revenue growth reflected higher volume, partly offset by lower realized prices. U.S. revenue rose 12% to $14.23 billion; revenue outside the U.S. rose 7% to $10.31 billion. Gross-margin pressure reflected lower realized prices, foreign-exchange effects on international inventories, higher Retevmo amortization, and bamlanivimab sales, partly offset by manufacturing efficiencies and prior-year Lartruvo withdrawal charges.
Research and development expense was $6.09 billion, up 9%, including approximately $450 million for COVID-19 therapies; excluding those costs, R&D was relatively flat. Marketing, selling, and administrative expense decreased 1% to $6.12 billion. Acquired in-process R&D charges were $660 million, versus $240 million in 2019.
At year-end, cash and cash equivalents were $3.66 billion and total investments were approximately $2.99 billion. Total debt was $16.60 billion, up from $15.32 billion; unused committed bank credit facilities totaled $5.24 billion. Capital expenditures were $1.39 billion. Lilly paid $2.96 per share in dividends during 2020 and raised the indicated annual dividend rate for 2021 to $3.40 per share. It repurchased $500 million of shares in 2020 and had $1.00 billion remaining under its authorized program.
Material changes versus the prior year
- Continuing-operations earnings increased, but total net income and diluted EPS declined because 2019 included an approximately $3.7 billion gain on the Elanco disposition. Lilly now reports one pharmaceutical segment.
- Key growth products included Trulicity ($5.07 billion, +23%), Taltz ($1.79 billion, +31%), Jardiance ($1.15 billion, +22%), Verzenio ($913 million, +57%), and Olumiant ($639 million, +50%). Bamlanivimab generated $871 million of 2020 revenue under emergency authorization.
- Some established products declined: Humalog revenue fell 7% to $2.63 billion, Forteo fell 26% to $1.05 billion, and Cialis fell 32% to $607 million. Patent loss and competition remain material headwinds.
- Investment gains contributed substantially to 2020 other income: net investment gains were approximately $1.44 billion, versus $401 million in 2019. The effective tax rate increased to 14.3% from 11.9%.
- Debt increased, while operating cash flow improved. Cash generation and liquidity were not negatively affected by COVID-19 in 2020, according to management.
Outlook, risks, contingencies, and unusual items
For 2021, management forecast revenue of $26.5 billion to $28.0 billion, including $1 billion to $2 billion from COVID-19 therapies, and diluted EPS of $7.10 to $7.75, excluding estimated Prevail acquisition and integration costs. It expected gross margin of approximately 77%, R&D expense of $6.5 billion to $6.7 billion (including $300 million to $400 million for COVID-19 therapies), marketing and administrative expense of $6.2 billion to $6.4 billion, other-net expense of $200 million to $300 million, and an effective tax rate near 15%.
Management expected mid-single-digit global net price declines in 2021, with low-to-mid-single-digit declines in the U.S. Forecast growth drivers included Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Cyramza, Emgality, Tyvyt, Retevmo, and COVID-19 therapies; losses of exclusivity were expected to offset some growth.
- COVID-19: The pandemic affected prescriptions, patient access, payer mix, trials, and commercial interactions. COVID-19 treatment demand could be reduced by vaccines, competing therapies, virus variants, or termination or revocation of emergency authorizations; returns, supply constraints, and manufacturing costs are additional uncertainties.
- Patent and competition exposure: Lilly expected Alimta generic entry in Europe and Japan from 2021 and limited U.S. entry in February 2022, followed by unlimited entry in April 2022. Forteo faced generic and biosimilar competition, and Cymbalta generics were expected in Japan in mid-2021. Insulin competition and pricing pressure could also erode share and prices.
- Legal and regulatory matters: Lilly is involved in product-liability, insulin-pricing, patent, and other proceedings and is self-insured for product-liability losses. It stated that outcomes generally could not be estimated reliably and could be material to results in a single period. A Brazil labor-related matter included an inflation- and interest-adjusted award estimated at about $180 million at year-end 2020, with appeals and enforcement issues ongoing.
- Pricing and reimbursement: U.S. rebate and discount liabilities were $5.85 billion at year-end. Policy changes, payer negotiations, drug-importation proposals, and the 340B contract-pharmacy dispute could affect access, prices, and results.
- Other risks: R&D failure, manufacturing or supplier disruption, cybersecurity, foreign-exchange movements, tax assessments, and evolving regulation could adversely affect performance. The filing identifies a $2.40 billion remaining Toll Tax payment obligation, including $254 million due in less than one year.
Auditors issued unqualified opinions on the financial statements and internal control over financial reporting. The audit identified sales rebate accruals and valuation of retirement-plan alternative investments as critical audit matters.
Important facts for investors to verify
- Whether 2021 revenue and EPS guidance was achieved, and how much revenue came from COVID-19 therapies versus the underlying portfolio.
- Actual net price and volume trends, particularly for U.S. diabetes products, and the development of rebate and discount liabilities.
- Timing and commercial impact of generic or biosimilar entry for Alimta, Forteo, Cymbalta, insulin products, and other exposed medicines.
- Pipeline trial outcomes and regulatory status, including confirmatory evidence required for accelerated or conditional approvals.
- Developments in insulin-pricing and 340B litigation, product-liability matters, and the Brazil labor litigation, including any changes to accrued exposures.
- Cash-flow conversion, debt levels, acquisition spending, and the contribution of investment gains to reported earnings.